secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001193125-23-085566
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics reports Q4 net income of $26.8M; GSK deal provides $66M upfront
--------------------------------------------------------------------------------

- Q4 2022 net income $26.8M ($0.55 EPS) vs net loss $29.2M in Q4 2021; full-year net loss $46.4M ($1.23 loss per share).
- Total revenue Q4 2022 $47.4M (up from $2.7M) driven by $46.1M collaboration revenue from GSK and Pfizer deals.
- Cash and equivalents $109.1M as of Dec 31, 2022; company expects runway beyond 2024.
- Initiated Phase 2 trial of SPR720 in NTM-PD; top-line data expected in first half of 2024.
- GSK license for tebipenem HBr: $66M upfront, $9M equity investment, up to $525M milestones plus tiered royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523085566/0001193125-23-085566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523085566/d438825d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-085566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer